HOME >> BIOLOGY >> NEWS
EMBO and Chinese Academy of Sciences join efforts in the area of the life sciences

The European Molecular Biology Organization (EMBO) and the Chinese Academy of Sciences (CAS) have signed an agreement to enhance collaboration with each other over the next two years. This is the first cooperation agreement with another scientific organization that EMBO has signed during its 40 years of existence. It is designed to support life science researchers from China and Europe who wish to cooperate through fellowships and joint meetings.

"The significance of this agreement is two-fold. First of all, it consolidates our working relationship with the Chinese scientific community and secondly, it shows that EMBO is actively building links with scientific organizations throughout the world", says Frank Gannon, EMBO Executive Director.

Under their new agreement, both EMBO and CAS, will encourage researchers from China and Europe to enter into or intensify scientific collaborations with each other in the field of life sciences. To ensure that such co-operation will be beneficial to the development of science in Europe and China, the two organizations will identify priority areas for mutual aid with a view to establishing at least one large research project.

"The Chinese Academy of Sciences, the highest organization of natural sciences in China and a major player in the Chinese scientific community is pleased to see the signing of this agreement. It will open new possibilities for Chinese-European co-operation. This holds especially true for young life scientists on both sides," says Chen Zhu, Vice President of the Chinese Academy of Sciences.

Last year EMBO added a medium-term fellowship scheme directed at scientists from emerging economies to its portfolio. As part of the new agreement, two such fellowships will be awarded to young Chinese scientists from CAS laboratories. This will allow Chinese life science researchers to visit European laboratories for six to nine months periods. In return, the Chinese Academy of Sciences has
'"/>

Contact: Ellen Peerenboom
ellen.peerenboom@embo.org
0049-6221-8891-108
European Molecular Biology Laboratory
28-Jan-2003


Page: 1 2

Related biology news :

1. Illustrated guidebook published for Chinese biomedical scientists and students
2. Skin condition linked to genetics in Caucasian and Chinese populations
3. Field Museum gives Parker/Gentry Award to Chinese conservationist
4. Ten Chinese reporters receive AAAS Fellowships
5. Studies probe rapid evolution of Chinese tallow trees
6. Oncologists evaluate Chinese herbal medicine
7. Chinese tallow tree invades Texas prairies
8. Ancient Chinese folk remedy may hold key to non-toxic cancer treatment
9. Sea Grant study finds Chinese mitten crabs appear free of human parasite lung flukes
10. Nutrient in cruciferous vegetables protects against lung cancer in study of 18,244 Chinese; benefit depends on genetic factor
11. Chinese dragon nears extinction, biologists warn

Post Your Comments:
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
Cached News: